PCF 2019 VL

Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James

Details
Nick James, a Professor of Clinical Oncology at the Institute of Cancer Research joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses the developments around the high-volume/low-volume disease in metastatic hormone-sensitive disease from the STAMPEDE trial. They also discuss relapsed disease versus de novo metastatic disease. Biographies: P...

Monoallelic vs Biallelic BRCA2 Alterations, PARP Inhibitors in Prostate Cancer - Colin Pritchard

Details
Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...

Prostate Cancer Foundation's Women in Science Forum Discussion - Himisha Beltran, Lorelei Mucci, Karen Knudsen, and Amina Zoubeidi

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Alicia Morgans is joined by the four women leaders and organizers of the Prostate Cancer Foundation's Women in Science Forum 2019. Himisha Beltran, Lorelei Mucci, Karen Knudsen, and Amina Zoubeidi each share their insights and motivations for leading the forum. Each of these professionals is moving the field forward...

Prostate 8 Program - Lifestyle, Exercise, and Nutrition - Stacey Kenfield

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Stacey Kenfield joins Charles Ryan to speak about her work on lifestyle, exercise, nutrition and its impact on prostate cancer. She talks about the Prostate 8 program which resulted from looking at men with prostate cancer and studying different dietary and lifestyle factors that might be associated with prostate can...

The Biology of Prostate Cancer - Kenneth Pienta

Details
Kenneth Pienta joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019) to discuss the biology of prostate cancer, and to share a clinician's perspective of thinking about the biology of this disease. This is a look at the current year and some of the significant findings that have changed the way we look at treating prostate cancer. The STAMPEDE data sho...

Integrating PARP inhibitors into the Standard of Care for Prostate Cancer - Joaquin Mateo

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Joaquin Mateo, Principal Investigator, and Translational Scientist at the Vall d'Hebron hospital in Barcelona joins Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of th...

Antibody-drug conjugates for metastatic urothelial carcinoma & 177Lu-PSMA-617 for Progressive mCRPC - Scott Tagawa

Details
Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) in urothelial cancer and his presentation from ESMO on the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide another option for patients...

"Eat, Move, Sleep" - June Chan

Details
At the 26th Annual Prostate Cancer Foundation Scientific Retreat 2019 (PCF 2019), Professor June Chan joins Charles Ryan to discuss her study "Eat, Move, Sleep," a digital cohort study that is focused on cancer survivorship aiming to collect data on diet, exercise, sleep, and other lifestyle practices in people with prostate, colorectal, and/or bladder cancer. This study is set to open in early 20...

The DORA Trial, Comparing Overall Survival in Patients Treated with Docetaxel vs. Docetaxel plus Radium-223 - Michael Morris

Details
Michael Morris, Professor of Medicine and GU Medical Oncologist, Memorial Sloan Kettering Cancer Center joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to discuss the DORA trial. Michael Morris is The DORA trial principal investigator for this Prostate Cancer Clinical Trials Consortium (PCCTC) trial. The primary objective of this study is to compare...

Clinical Implications of the CARD Trial - Cora Sternberg

Details
In this conversation, Alicia Morgans and Cora Sternberg, Medical Oncologist and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine in New York discuss the recently presented results from the CARD trial. The CARD Trial a phase 4 clinical trial compared cabazitaxel vs abiraterone or enzalutamide in patients who were previously treated with docetaxel and had p...